Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
SANTA MONICA, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (NASDAQ:KITE) today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 8:30 AM Pacific Time. The event will be held in San Francisco at the Westin St. Francis Hotel.
The presentation will be webcasted and will be available through the Calendar of Events section of Kite's website at ir.kitepharma.com.
About Kite Pharma, Inc.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Kite Pharma, Inc. Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Lisa Burns Burns McClellan (212) 213-0006 [email protected] [email protected]
